Viewing nowCombinationTraduo M-Pass Extended Release Tablet 25/5/1000 mg (Empagliflozin, Linagliptin, Metformin)
Empagliflozin 25mg · Linagliptin 5mg +1 more
Tablet · Prescription medication · Combination
(Co., Ltd.) Yuhan Corporation

MFDS item code 202501956 · Approved 2025.07.29 · Insurance code 642106360
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps improve blood sugar control in patients with type 2 diabetes. It is used in conjunction with empagliflozin, linagliptin, and metformin to assist with dietary and exercise therapy. This helps effectively manage blood sugar levels and contributes to the prevention of complications, allowing patients to maintain a healthier blood sugar state in their daily lives.
For antidiabetic therapy, determine the dose of this drug based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily dose of each component: empagliflozin 25mg, linagliptin 5mg, and metformin hydrochloride extended-release 2000mg. Take this drug once daily in the evening with a meal to reduce gastrointestinal adverse reactions caused by metformin hydrochloride. If the metformin hydrochloride dose needs adjustment, adjust it gradually. Patients taking this drug as extended-release tablets containing 10/5/1000 mg or 25/5/1000 mg should take 1 tablet once daily. If the recommended starting dose of this drug, empagliflozin 10 mg/linagliptin 5 mg/metformin hydrochloride 1000mg once daily, is well tolerated and additional glycemic control is needed, the dose may be increased to 25/5/1000 mg once daily. Patients switching from combination therapy with empagliflozin, linagliptin, and metformin hydrochloride to this drug should receive their previous doses. The safety and efficacy of this drug have not been specifically evaluated in patients switching from other glucose-lowering drugs. Because such a switch may result in changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made with careful monitoring. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. To maintain the extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. This drug may not dissolve completely and may be excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the drug. If the patient repeatedly reports finding this drug in the feces, the healthcare provider should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Special populations Patients with renal impairment The efficacy and safety of this drug vary according to renal function, and dose adjustment based on renal function is required. Therefore, assessment of renal function is recommended before starting this drug and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used by adjusting the dose of the metformin hydrochloride component. The starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, discontinue this drug immediately. Renal function should be assessed every 3~6 months.
This medication can rarely cause a serious metabolic complication called lactic acidosis, which has been associated with reported cases of death. Therefore, it should not be used in patients with severely impaired kidney function, acute or chronic metabolic acidosis, or those undergoing dialysis. Additionally, it should be avoided in patients with severe heart failure or unstable physical conditions such as acute myocardial infarction, shock, or severe infections. Medication should be temporarily stopped before and after examinations using radiologic iodine contrast agents due to the risk of kidney damage and lactic acidosis. The level of the drug in the blood may vary depending on kidney function, so periodic kidney function tests are required before and during treatment. Special attention is needed for elderly patients or those with impaired kidney function. Careful monitoring is also required for patients with heart failure or a history of pancreatitis; if symptoms of acute pancreatitis occur, medication should be discontinued immediately. This medication may cause hypoglycemia, so dosage adjustments may be necessary to reduce the risk of hypoglycemia when used in conjunction with drugs that induce hypoglycemia, such as insulin or sulfonylureas. Irregular meals, vigorous exercise, and excessive alcohol intake may also increase the risk of hypoglycemia or lactic acidosis. Various side effects such as urinary tract infections, genital fungal infections, increased urination, decreased fluid volume, and abnormal liver function may occur during treatment with this medication; patients should consult their healthcare provider if unusual symptoms arise. Especially, if pain or swelling occurs around the perineum, immediate medical attention should be sought. The risk of lactic acidosis may increase when taken with alcohol, so excessive drinking should be avoided during treatment. Additionally, there may be interactions with other medications, so it is essential to inform healthcare providers of any other medications being taken. Finally, tablets should be swallowed whole without chewing or crushing, and while the drug shell may appear in stool, this is a normal occurrence.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from exposure to air or moisture. Additionally, it is recommended to store the medication at room temperature between 1°C and 30°C, avoiding extremely cold or hot places.
Pink oval film-coated extended release tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 25mg · Linagliptin 5mg +1 more
Tablet · Prescription medication · Combination
(Co., Ltd.) Yuhan Corporation
CombinationEmpagliflozin 10mg · Linagliptin 5mg +1 more
Tablet · Prescription medication · Combination
Yuhan Corporation
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.